-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34

Benzinga·07/23/2026 14:13:50
Listen to the news
B. Riley Securities analyst William Woods initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $34.